Evelyn Partners Investment Management Europe Ltd Purchases 11,776 Shares of Johnson & Johnson $JNJ

Evelyn Partners Investment Management Europe Ltd boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 11,109.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,882 shares of the company’s stock after purchasing an additional 11,776 shares during the period. Johnson & Johnson comprises about 2.1% of Evelyn Partners Investment Management Europe Ltd’s investment portfolio, making the stock its 13th biggest position. Evelyn Partners Investment Management Europe Ltd’s holdings in Johnson & Johnson were worth $1,815,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in JNJ. W.H. Cornerstone Investments Inc. raised its stake in shares of Johnson & Johnson by 0.7% in the second quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock valued at $1,206,000 after acquiring an additional 58 shares during the last quarter. YANKCOM Partnership raised its position in Johnson & Johnson by 0.8% in the 2nd quarter. YANKCOM Partnership now owns 7,042 shares of the company’s stock valued at $1,076,000 after purchasing an additional 58 shares during the last quarter. Greenup Street Wealth Management LLC boosted its stake in Johnson & Johnson by 3.1% in the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock worth $309,000 after purchasing an additional 60 shares in the last quarter. Ellis Investment Partners LLC grew its holdings in shares of Johnson & Johnson by 0.7% during the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after purchasing an additional 62 shares during the last quarter. Finally, Cypress Wealth Services LLC increased its stake in shares of Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock valued at $1,013,000 after buying an additional 62 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on JNJ. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Scotiabank assumed coverage on shares of Johnson & Johnson in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 price target on the stock. Argus set a $210.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 15th. Raymond James Financial upped their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Finally, Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a research note on Monday, October 20th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $201.05.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $203.88 on Friday. The firm’s 50 day moving average price is $188.25 and its two-hundred day moving average price is $171.55. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $206.94. The stock has a market cap of $491.21 billion, a PE ratio of 19.68, a PEG ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.